362489-61-0

Usage

Chemical class

Piperidine derivatives

Common usage

Medicinal chemistry and drug discovery studies

Substituents

1-tert-butyl and 3-methyl group

Functional groups

Two carboxylate groups at the 1 and 3 positions

Stereochemistry

(3S,4R) indicating the configuration of the substituents on the piperidine ring

Potential properties

Pharmacological properties, ability to interact with biological targets

Applications

Development of new pharmaceuticals or as a research tool in chemical biology

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 161491-24-3 methyl 1-tert-butoxycarbonyl-4-oxo-3-piperidinecarboxylate 
• 362489-60-9 1-tert-butyl 3-methyl (3S,4R)-4-{[(1R)-1-phenylethyl]-amino}piperidine-1,3-dicarboxylate 
• 503167-62-2 C₂₀H₃₀N₂O₄ 

Downstream Products

• 362489-62-1 C₃₀H₃₅N₃O₆ 
• 859855-26-8 (3S,4R)-1-tert-butyl 3-methyl 4-(benzyloxycarbonylamino)piperidine-1,3-dicarboxylate 

Relevant academic research and scientific papers

Effect of a: Cis -4-aminopiperidine-3-carboxylic acid (cis -APiC) residue on mixed-helical folding of unnatural peptides

The α/β-peptide 11/9-helix and the β-peptide 12/10-helix belong to mixed helices, in which two types of hydrogen bonds with opposite directionality alternate along the helical axis. cis-2-Aminocyclohexanecarboxylic acid (cis-ACHC) is known to promote these mixed helices and stabilize the helical propensity more than other acyclic β-residues. Application of a mixed-helical backbone still requires sufficient solubility in aqueous solution. In this regard, we chose cis-4-aminopiperidine-3-carboxylic acid (cis-APiC) as a foldamer building block that can provide both sufficient aqueous solubility and mixed-helical propensity. Conformational analyses of α/β- and β-peptides containing a cis-APiC residue by circular dichroism spectroscopy and single-crystal X-ray crystallography suggest that the incorporation of cis-APiC instead of cis-ACHC can enhance the aqueous solubility of the mixed-helical peptides without any adverse effect on helical folding. In addition, the ratio between right- and left-handed 12/10-helices of β-peptides can be rationalized by relative energies between the local conformations of the cis-APiC residue. This journal is

Efficient and practical asymmetric synthesis of 1-tert-butyl 3-methyl (3R,4R)-4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidine-1,3-dicarboxylate, a useful intermediate for the synthesis of nociceptin antagonists

An efficient and practical asymmetric synthesis of 1-tert-butyl 3-methyl (3R,4R)-4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidine-1,3-dicarboxylate 1, a useful intermediate for the synthesis of nociceptin antagonists, has been developed. This method i

Discovery of β-benzamido hydroxamic acids as potent, selective, and orally bioavailable TACE inhibitors

β-Benzamido hydroxamic acids were discovered as potent TACE inhibitors. A computer model was constructed to help understanding the binding activities and guiding SAR study. SAR optimization led to the discovery of compound 30 which met all in vitro and in

Cyclic derivatives as modulators of chemokine receptor activity

The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the treatment of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma.

PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS

The present invention provides compounds of formula (I); and pharmaceutically acceptable salts thereof. The formula (I) compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula (I) compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.